Skip Navigation


European Heart Journal Advance Access originally published online on February 4, 2005
European Heart Journal 2005 26(6):538-543; doi:10.1093/eurheartj/ehi145
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/6/538    most recent
ehi145v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sanghi, P.
Right arrow Articles by Schwarz, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanghi, P.
Right arrow Articles by Schwarz, E. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Vasopressin antagonism: a future treatment option in heart failure

Pramod Sanghi, Barry F. Uretsky and Ernst R. Schwarz*

Divison of Cardiology, Department of Internal Medicine, The University of Texas Medical Branch, School of Medicine, 5.106 John Sealy Annex, 301 University Blvd, Galveston, TX 77555-0553, USA

Received 11 June 2004; revised 23 November 2004; accepted 16 December 2004; online publish-ahead-of-print 4 February 2005.

* Corresponding author. Tel: +1 409 772 9835; fax: +1 409 772 4982. E-mail address: erschwar{at}utmb.edu

Arginine vasopressin plays an important role in volume homeostasis. Patients with heart failure have chronically elevated plasma vasopressin concentrations which may contribute to their clinical syndrome of fluid retention. Recently, a number of agents have been developed to antagonize the effects of vasopressin by targeting its V1a and V2 receptors, which are involved in vascular tone and free water regulation, respectively. Two vasopressin antagonists, in particular, tolvaptan and conivaptan, have shown promise in animal studies and small-scale human trials. The following is a review of current experimental and clinical studies using vasopressin antagonists and their potential role in the treatment of heart failure.

Key Words: Vasopressin • Antidiuretic hormone • Heart failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
K. A. Walter
Conivaptan: New treatment for hyponatremia
Am. J. Health Syst. Pharm., July 1, 2007; 64(13): 1385 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
E. Cristia, C. Amat, R. J. Naftalin, and M. Moreto
Role of vasopressin in rat distal colon function
J. Physiol., January 15, 2007; 578(2): 413 - 424.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley
Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.